CRISPR-RIC-LNP

CRISPR-RIC-LNP (also known as CR-Ric-LNP) is a preclinical lipid nanoparticle (LNP) formulation delivering a CRISPR-Cas12a ribonuclease complex designed to target and knock out the RICTOR gene. Developed by researchers at the Houston Methodist Research Institute, the therapy specifically targets myeloid cells, such as tumor-associated macrophages (TAMs), in the tumor microenvironment. By silencing RICTOR, a critical component of the mTORC2 complex, CRISPR-RIC-LNP reprograms immunosuppressive, pro-tumorigenic M2-like TAMs into pro-inflammatory, anti-tumorigenic M1-like macrophages. This remodeling of the tumor microenvironment enhances cytotoxic T-cell activation and reduces regulatory T-cell populations, demonstrating therapeutic efficacy in preclinical models of breast cancer liver metastasis.

Other names

CRISPR Rictor-targeting iLNPCRISPR-LNP targeting RICTORCRISPR-RICTOR-LNP